Hereditary Breast and Ovarian Cancer (HBOC) (Germline)

Product Code: 01-HBOC-NOOP-26

From £449.00 Early Bird

Early Bird Deadline: 31/10/2025

Deadline to order: 30/11/2025

BRCA1/BRCA2 or panel testing for hereditary breast and ovarian cancer (HBOC) (Germline DNA), this EQA has options for targeted or panel testing

Target/Genes:

Genes associated with Hereditary Breast and Ovarian Cancer. This EQA has options for:

Targeted BRCA1/BRCA2 testing
Hereditary Breast and Ovarian Cancer panel testing.

The scope of the panel testing EQA option is broadly in line with the genes designated high evidence (green) on the Genomics England Inherited breast cancer and ovarian cancer panel list app. Laboratories which test the BRCA1/BRCA2 genes in the context of targeted therapies (e.g., PARP inhibitors) should register for the appropriate schemes for Germline testing (02-PARP-GERM-26), Somatic testing (02-PARP-SOMA-26) and cfDNA testing (02-PARP-PLAS-26).This scheme is not suitable for laboratories testing for recurrent variants only.

Technology:

CNV, MLPA, NGS, Panel testing, Sanger sequencing, Whole exome sequencing, Whole genome sequencing

Language:

English, French, German, Italian, Spanish

Sample Type:

DNA (in TE Buffer)

Accredited:

Yes

Sample Dispatch Date:

January 2026

Survey Period:

January - March 2026

Final Results:

August 2026

Buy Scheme Add to Wishlist

You can complete purchase on our secure partner site.

EQA Assessment

The scheme is designed to assess the entire diagnostic pipeline of a laboratory, including sample receipt and processing, analytical processing (genotyping), and reporting (biological and clinical interpretation of the test result) in the context of a clinical referral, as well as reporting clarity, content and clerical accuracy.

Sample Details

Three mock clinical cases; 2 with matching samples and 1 virtual case will be provided.

Approximately 2µg DNA per sample is provided. Complete information will be available in scheme instructions.

EQA Results

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results. Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Participation Information

Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.

Panel testing can be performed using any appropriate panel for genes associated with hereditary breast and ovarian cancer. To account for differing panel compositions, variants outside the stated scope of an individual laboratory’s panel will be excluded from their assessment. Only variants that have been validated in the test samples will be assessed.

No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).

How it works

Register

Enrol before the closing date
EMQN ships EQA samples or digital cases

Test & submit results

Analyse samples in your routine workflow
Upload results via your website account

Review & get certified

EMQN assesses your data
Receive your individual results, EQA summary report & certificate of participation

Enquire about this scheme

Contact Information

office@emqn.org

Phone

+44 161 757 1591